Is It Time To Revisit IQVIA (IQV) After Its Sharp Year To Date Share Price Drop

• If you are wondering whether IQVIA Holdings is priced fairly or if the recent share price is offering you an opening, this article focuses squarely on what the current valuation is indicating.
• The stock last closed at US$158.98, with returns of 3.6% over 1 year, but year to date the share price is down 29.5%. This includes a 9.5% fall over the past week and a 3% decline over the past month.
• These moves sit against a longer backdrop where the stock shows a 14.3% decline over 3 years and a 31.7% decline over 5 years. This may shape how investors think about risk and required returns today. This context matters when weighing any valuation signal and deciding how much of that history you think is already reflected in the price.
• IQVIA Holdings currently scores 6 out of 6 on our valuation checks. Next, you will see how different valuation approaches arrive at that score, followed by a more rounded way to think about what the stock might be worth.

IQVIA Holdings delivered 3.6% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: IQVIA Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting them back to today using a required rate of return. It is essentially asking what those future dollars are worth in today’s money.

For IQVIA Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about US$2.01b. Analysts provide detailed estimates out to 2030, where free cash flow is projected at US$3.30b. Beyond those analyst years, Simply Wall St extrapolates additional annual cash flows. In this model they extend out to 2035 to complete the second stage of the DCF.

When all of those projected cash flows are discounted back and aggregated, the model arrives at an estimated intrinsic value of US$312.09 per share. Against the recent share price of US$158.98, this implies a 49.1% discount, which points to IQVIA Holdings trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests IQVIA Holdings is undervalued by 49.1%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for IQVIA Holdings.

Approach 2: IQVIA Holdings Price vs Earnings

For profitable companies, the P/E ratio is a straightforward way to connect the share price with the earnings that support it. It lets you see how many dollars you are paying for each dollar of current earnings, which is often a simple starting point when you already have positive profits.

What counts as a “normal” or “fair” P/E ratio usually depends on how fast earnings are expected to grow and how risky those earnings appear. Higher growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk often goes with a lower P/E.

IQVIA Holdings currently trades on a P/E of 19.62x. That sits below the Life Sciences industry average P/E of 34.40x and the peer average of 34.64x. Simply Wall St also provides a proprietary “Fair Ratio” of 22.56x, which estimates the P/E that might be appropriate for IQVIA Holdings given factors like its earnings growth profile, industry, profit margins, market capitalization and company specific risks.

This Fair Ratio can be more tailored than a simple comparison with peers or the industry, because it adjusts for IQVIA Holdings own characteristics rather than assuming it should match the group. Compared with this 22.56x Fair Ratio, the current 19.62x P/E suggests the shares are trading below that model based estimate.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your IQVIA Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to write the story you believe about IQVIA Holdings, connect that story to a forecast for revenue, earnings and margins, and then see the Fair Value that drops out of those assumptions.

On Simply Wall St, Narratives live in the Community page and let you plug in your own view. For example, one Narrative for IQVIA Holdings might lean closer to the higher analyst fair value of about US$290.00 with revenue growth assumptions near 7.65% and profit margins around 10.90%. Another might sit nearer the lower US$200.00 Narrative that uses revenue growth of about 5.57% and profit margins around 8.82%.

Each Narrative links this kind of story to a Fair Value, compares it with the latest share price, and updates when new information like news, earnings or guidance is added. This lets you quickly see whether your chosen IQVIA Holdings Narrative suggests the stock is trading above or below what you think it is worth and decide how that lines up with your own buy or sell rules.

Do you think there's more to the story for IQVIA Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com